MarketPulse

antibody engineering

2 articles
BenzingaBenzinga··Globe Newswire

Spyre Therapeutics Raises $300M in IPO as IBD-Focused Biotech Advances Pipeline

Clinical-stage biotech Spyre Therapeutics launches $300M public offering to fund inflammatory bowel disease drug development, with major investment banks leading.
SYREpublic offeringcapital raise
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Spyre Therapeutics Raises $300M in IPO to Fund IBD Drug Development

Clinical-stage biotech Spyre Therapeutics announced $300M public offering with $45M underwriter option, led by Jefferies and Goldman Sachs, targeting IBD treatments.
SYREpublic offeringcapital raise